



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Pratt, et al.
SERIAL NUMBER: 10/723,626 EXAMINER : Not Yet Assigned
FILING DATE: November 26, 2003 ART UNIT : 1616
FOR: BUOYANT POLYMER PARTICLES FOR DELIVERY OF
THERAPEUTIC AGENTS TO THE CENTRAL NERVOUS SYSTEM

MAIL STOP IDS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.


It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

03-30-04

Express Mail Label No.: EV 312714957 US
Date of Deposit: March 29, 2004

Attorney Docket No.: 19043-501



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Pratt, et al.
SERIAL NUMBER: 10/723,626 EXAMINER : Not Yet Assigned
FILING DATE: November 26, 2003 ART UNIT : 1616
FOR: BUOYANT POLYMER PARTICLES FOR DELIVERY OF
THERAPEUTIC AGENTS TO THE CENTRAL NERVOUS SYSTEM

Mail Stop IDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Copies of Cited References: A1-2; C1-34; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 19043-501. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

A handwritten signature in black ink that reads 'Ingrid A. Beattie'.

Ingrid A. Beattie, Reg. No. 42,306
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Dated: March 29, 2004

APPLICANT: Pratt, et al.
U.S.S.N.: 10/723,626

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 19043-501.

Respectfully submitted,



Ingrid A. Beattie (Registration No. 42,306)

Attorneys for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Customer No. 30623

Date: March 29, 2004

TRA 1902503v1



Please type a plus sign (+) in this box



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/723,626	
				Filing Date		November 26, 2003	
				First Named Inventor		Pratt	
				Group Art Unit		1616	
				Examiner Name		Not Yet Assigned	
				Attorney Docket Number		19043-501	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,455,044	10/03/95	Kim, et al.	424	450	
	A2	5,576,018	11/19/96	Kim, et al.	424	450	
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No	
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1	Adibhatla, et al., <i>J. Neurochem.</i> , 80(1):12-23 (2002).					
	C2	Agut, et al., <i>Arzneitm. Forsch. Drug Res.</i> , 33(II):1045-1047 (1983).					
	C3	Bawa, et al., <i>J. Controlled Release</i> , 1:259-267 (1985).					
	C4	Benowitz, et al., <i>J. Biol. Chem.</i> , 273(45):29626-29634 (1998).					
	C5	Brem, et al., <i>J. Neurosurg.</i> , 74:441-446 (1991).					
	C6	Brown, et al., <i>J. Pharm. Sci.</i> , 72(10):1181-1185					
	C7	Camarata, et al., <i>Neurosurg.</i> , 30(3):313-319 (1992).					
	C8	Chen, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 99(13):9031-9036 (2002).					
	C9	Fresta, et al., <i>Pharm. Res.</i> , 12(11):1769-1774 (1995).					
	C10	Goodell, et al., <i>Am. J. Hospital Pharm.</i> , 43(6):1454-1461 (1986).					
	C11	Göppferich, A., <i>Macromolecules</i> , 30(9):2598-2604 (1997).					
	C12	Grill, et al., <i>J. Neurosci.</i> , 17(14):5560-5572 (1997).					
	C13	Hansch, et al., <i>J. Med. Chem.</i> , 11(1):1-11 (1967).					
	C14	Harbaugh, R.E., <i>Psychopharmacol. Bulletin</i> , 22(1):106-109 (1986).					
	C15	Hatcher, et al., <i>Soc. Neurosci., Abstract only</i> , 25:583 (1999).					
	C16	Hentze, et al., <i>Rev. Mol. Biotech.</i> , 90(1):27-53 (2002).					
	C17	Kammersgaard, et al., <i>Stroke</i> , 31:2251-2256 (2000).					
	C18	Kawashima, et al., <i>J. Controlled Release</i> , 16(3):279-289 (1991).					
	C19	Langer, et al., <i>J. Macromol. Sci. – Rev. Macromol. Chem. Phys.</i> , C23(1):61-126 (1983).					

	C20	Langer, et al., in <i>Biomedical Polymers, polymeric materials and pharmaceuticals for biomedical use</i> , Goldberg, E.P., Nakagim, A. (eds.), Academic Press, pp. 113-137 (1980).
	C21	Langer, R., <i>J. Controlled Release</i> , 16(1-2):53-59 (1991).
	C22	Lazorthes, et al., in <i>Advances in Drug Delivery Systems and Applications in Neurosurgery</i> , 18:143-192 (1991).
	C23	Lee, et al., <i>J. Microencapsulation</i> , 18(1):65-75 (2001).
	C24	Lee, et al., <i>J. Microencapsulation</i> , 16(6):715-729 (1999).
	C25	Levin, et al., <i>Anesthesia and Analgesia</i> , 60(11):814-817 (1981).
	C26	Menei, et al., <i>Neurosurg.</i> , 34(6):1058-1064 (1994).
	C27	Noor, et al., <i>Med. Sci. Monit.</i> , 8(9):RA210-RA215 (2002).
	C28	Ommaya, A.K., <i>Cancer Drug Delivery</i> , 1(2):169-179 (1984).
	C29	Petrausch, et al., <i>J. Neurosci.</i> , 20(21):8031-8041 (2000).
	C30	Rao, et al., <i>J. Neurosci. Res.</i> , 58(5):697-705 (1999).
	C31	Rhine, et al., <i>J. Pharm. Sci.</i> , 69(3):265-270 (1980).
	C32	Secades, et al., <i>Meth. Find. Exp. Clin. Pharmacol.</i> , 17Suppl. B):1-54 (1995).
	C33	Weiss, G.B., <i>Life Sci.</i> , 56(9):637-660 (1995).
	C34	Winn, et al., <i>Experimental Neurol.</i> , 105(3):244-250 (1989).

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.